ArticleWorld journal of urology2021
Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomes.
Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Outcomes of Water Vapor Thermal Therapy (REZUM) in Management of Symptomatic Patients With Benign Prostatic Enlargement
Two-Year Follow-Up Comparing Rezūm Therapy Versus Bipolar Transurethral Resection of the Prostate for Treating Benign Prostatic Hyperplasia. A Prospective Randomized Study.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.Lower urinary tract symptoms · 2026Pooled it
- Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.World journal of urology · 2025Pooled it
- [Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4].Urologie (Heidelberg, Germany) · 2024Guideline
- Efficacy and safety of Water Vapor Thermal Therapy in the treatment of benign prostate hyperplasia: a systematic review and single-arm Meta-analysis.BMC urology · 2023Pooled it
- Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature.World journal of urology · 2023Pooled it
- Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: An Umbrella Review and Updated Meta-Analysis.The world journal of men's health · 2026Article
- Real-World Long-Term Outcomes of Rezūm Therapy for Large-Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study.Lower urinary tract symptoms · 2026Article
- Rezum: Analysis of the Tolerability and Complications of the Procedure Performed Under Local Anaesthetic.Journal of clinical medicine · 2026Article
- Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients.Prostate cancer and prostatic diseases · 2026Article
- Water vapor thermal therapy for patients with large prostates (≥ 80 mL): initial real-world data from China.International urology and nephrology · 2026Article
- Rezūm water vapor therapy vs. thulium laser enucleation for the treatment of benign prostatic hyperplasia in patients with large prostates: a multicenter prospective comparative study.Prostate cancer and prostatic diseases · 2025Article
- Introduction of a Structured Reporting Protocol and Surgical Checklist for Rezum Water Vapor Therapy (VAPOR-SRP).Journal of clinical medicine · 2025Article
- A comparative analysis of the outcomes of Rezūm therapy based on prostate size: a four-year retrospective analysis.World journal of urology · 2025Article
- Prostate Size and Its Effect on Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Improvement After Convective Water Vapor Thermal Therapy.The Journal of urology · 2025Article
- To Rezūm or Not to Rezūm: A Narrative Review of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia.Journal of clinical medicine · 2025Review
- Comparison of outcome for holmium laser enucleation prostate and Rezum system in benign prostate hyperplasia: a matched pair analysis.World journal of urology · 2025Article
- Real-world experience of water vapour therapy (Rezum) in patients with benign prostatic enlargement: a retrospective single-center study.Prostate cancer and prostatic diseases · 2025Article
- Expert consensus on Rezūm™: Indications, surgical technique and postoperative care.BJUI compass · 2025Review
- Water vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).World journal of urology · 2025Article
- Efficacy of Rezūm water vapor therapy for the treatment of catheter-dependent urinary retention A single-center, Canadian experience.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRezum is a minimally invasive surgery for benign prostatic hyperplasia. Current guidelines recommend Rezum for prostates < 80 cc, but little data exist describing outcomes in patients with prostates ≥ 80 cc. We compare outcomes after Rezum between men with small < 80 cc (SP) and large ≥ 80 cc prostates (LP).
methodsPatients undergoing Rezum between Jan 2017-Feb 2020 were subdivided by prostate volume (< 80, ≥ 80 cc). Outcomes were documented pre- and postoperatively. Descriptive analyses of urodynamics data (Qmax, PVR), symptom scores (AUA-SS, SHIM), disease management (medications, catheterization, retreatments), and clinical outcomes were conducted.
results36 (17.6%) men had prostates ≥ 80 cc (LP mean prostate size 106.8 cc). LP men had improved Qmax and PVR postoperatively; those with longitudinal follow-up exhibited improved Qmax, PVR, and AUA-SS. After one year, alpha-blocker usage decreased significantly (LP 94.44-61.11%, p = 0.001, SP 73.96-46.15%, p = 0.001); other medication usage and self-catheterization rates remained unchanged. Compared to SP patients, differences in passing trial void (LP 94.44%, SP 93.45%), postoperative UTI (LP 19.44%, SP 10.12%), ED visits (LP 22.22%, SP 17.86%), readmissions (LP 8.33%, SP 4.76%), and retreatment (LP 8.33%, SP 4.76%) were insignificant. However, mean days to foley removal (LP 9, SP 5.71, p = 0.003) and urosepsis rates (LP 5.56%, SP 0.00%, p = 0.002) differed.
conclusionIn select LP patients, Rezum provided short-term symptomatic relief and improved voiding function comparable to SP patients. Postoperatively, though alpha-blocker usage decreased significantly, use of other medications did not change, and nearly two-thirds of patients still needed alpha-blockade. Further efforts should explore the possibility of expanding Rezum's inclusion criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.